Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
about
Mechanisms of stress in the brainAntidepressant mechanism of ketamine: perspective from preclinical studiesAntidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradationCaV3.2 calcium channels control NMDA receptor-mediated transmission: a new mechanism for absence epilepsy.R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effectsComparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depressionA Clickable Analogue of Ketamine Retains NMDA Receptor Activity, Psychoactivity, and Accumulates in Neurons.The Combination of Long-term Ketamine and Extinction Training Contributes to Fear Erasure by Bdnf Methylation.Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with KetamineSynaptic mechanisms underlying persistent cocaine cravingCognitive dysfunction in major depression and Alzheimer's disease is associated with hippocampal-prefrontal cortex dysconnectivity.Investigational drugs for treating major depressive disorder.Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A₁ and A2A receptor activation.Novel Glutamatergic Treatments for Severe Mood Disorders.Hedonic sensitivity to low-dose ketamine is modulated by gonadal hormones in a sex-dependent mannerGene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress.Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress modelBrain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic TargetsKetamine for treatment-resistant depression: recent developments and clinical applications.New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders.What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine.Ketamine and Imipramine Reverse Transcriptional Signatures of Susceptibility and Induce Resilience-Specific Gene Expression Profiles.Modulating synaptic NMDA receptors.Increased EphA4-ephexin1 signaling in the medial prefrontal cortex plays a role in depression-like phenotype.Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.Delta Opioid Receptors and Modulation of Mood and Emotion.Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model.Single bolus low-dose of ketamine does not prevent postpartum depression: a randomized, double-blind, placebo-controlled, prospective clinical trial.Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus.Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.5-Hydroxytryptamine-independent antidepressant actions of (R)-ketamine in a chronic social defeat stress model.Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression.Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5.Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model.Acetyl-l-carnitine deficiency in patients with major depressive disorderLack of Antidepressant Effects of Low-Voltage-Sensitive T-Type Calcium Channel Blocker Ethosuximide in a Chronic Social Defeat Stress Model: Comparison with (R)-KetamineEradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
P2860
Q26781233-E2A8894F-10A4-43EC-8CD0-1621AF3F2933Q26800231-34CFBC1B-04CD-4A2B-89B5-64F99C8DEF25Q27319514-F4B4CB4A-65B8-4F18-8F25-3DF14689D1BAQ27323026-78FC6726-C313-4E41-BF2C-66366ABEC29DQ28266846-ADB3FB9D-BDB6-4960-9C29-0CD00C4C95B4Q28277636-069E8BB8-D7BA-4261-987C-CE3F4F4D4ECDQ28817259-ABC0FC0E-D301-49B4-B0FA-6F5F3859E521Q33583121-AA7EFF5D-29C5-42A9-8C81-CF11DF3E897EQ33614178-C0E77688-75A9-4B81-92D8-F6D80C8FA881Q33784838-B1541F43-D3D9-45F1-B774-A9DB10E602F9Q33812862-F6F373CB-C133-4E1E-9FEA-D9F907D92EEDQ34547274-BBAD31CF-6809-4702-BB30-38958233588EQ35587857-ADA3B8AC-2EF0-447D-9BD8-A71BCEE902DBQ36498659-48CB1028-93D1-4AEA-87F3-B9F507712F65Q36616952-0201FB33-6CBF-47E9-865C-1DAAE71A4DCDQ36770623-71EF8A8E-366C-4D1D-90C9-89BC579EB12CQ36915463-6DBD1D84-4A94-49D0-BEBB-819760A5B044Q37310546-3EC5BA96-F4B3-4FB9-BAFB-FF6B9B5316F7Q38800172-855BD3FC-050E-45B0-8554-3F0A9E8366F2Q38843745-65324E3B-D2E6-4FFD-8FE5-D57F785060C1Q39006234-B98D3C7C-95E7-4A78-9BBE-E38DA63C44B4Q39103844-2AB4988E-8D7C-41A2-AE40-3F33CD855A60Q39296220-4E7E9BED-B162-4165-BD61-1CEC019C7240Q39450031-07A6718A-2FF6-424C-BF1B-2C7543F11BF7Q40097393-71291964-53CD-4AE4-9063-7B0709E1ED2DQ43146252-0634AC97-FC29-4E9E-BFEC-CB9BE1239863Q44349588-14D09A83-6C16-4BC7-9C5A-6EA2472AB8D6Q46237980-3492418D-0681-4F49-ABF2-344B25A576CAQ47313887-D014A642-34FB-4D73-8994-42F0017950A5Q47342307-EEA17413-BCA1-48FB-AA80-A77B41A09DE7Q47396901-8A9CCFE5-A9C6-4F2A-9684-EB468E139310Q47572680-DC2E79F0-1121-40B3-914B-83F33824DE1EQ47572684-828DB29A-CF3B-4F6D-9988-D2A229199AF8Q47633542-71883F5F-A1AE-493F-A3E5-10735E8DF9E9Q48077200-426C9682-545B-458C-909B-10DCE2CEEC5BQ53441048-5ECDA1B6-5D24-47E7-A92A-D1B886B6FB7BQ56148475-ABDCA359-E2A2-41D4-A947-F69D3A81764CQ58798136-C09BCA84-5CD1-4EC9-9B77-64019B475C96Q59138279-5D68EF05-0C98-4411-99FE-F9E59123B7FE
P2860
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@ast
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@en
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@nl
type
label
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@ast
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@en
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@nl
prefLabel
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@ast
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@en
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@nl
P2860
P3181
P1476
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
@en
P2093
Carlos Zarate
P2860
P304
P3181
P356
10.1016/J.CONB.2014.12.004
P407
P577
2015-02-01T00:00:00Z